Back

Outcomes with early access tafamidis in patients with variant transthyretin amyloid cardiomyopathy

9 May 2026 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Amyloidosis and hypertrophic cardiomyopathy: emerging insights and clinical outcomes Pharmacotherapy Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Professor Ronald Witteles

Stanford University, Stanford (United States of America)

5 More presentations in this session

Presentation thumbnail
When imaging is not enough: diagnostic performance of endomyocardial biopsy in cardiac amyloidosis
Doctor J. AGOSTINHO (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Impact of iron deficiency on adverse outcomes in transthyretin cardiac amyloidosis
Doctor A. Martins (Leiria, PT)
Abstract Slides Video
Presentation thumbnail
Diagnostic lag and time to transthyretin stabilizer therapy in wild-type transthyretin amyloid cardiomyopathy
Professor C. Coleman (Storrs, US)
Abstract Slides Video
Presentation thumbnail
Tafamidis to treat patients with transthyretin cardiac amyloidosis (ATTR-CM): real-world data from a tertiary centre
Doctor M. Sobral Domingues (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Impact of SGLT2 inhibitors on functional class in patients with transthyretin cardiac amyloidosis: a retrospective matched study
Doctor R. Spoladore (Lecco, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Amyloidosis and hypertrophic cardiomyopathy: emerging insights and clinical outcomes

The Event

Event poster

Heart Failure 2026

9 May - 12 May 2026
You may be interested in
thumbnail
Congress Presentation
Tafamidis treatment for transthyretin amyloid cardiomyopathy: results from an open-label, early-access, long-term study extension in an all-comers population
thumbnail
Congress Presentation
Impact of Tafamidis on clinical outcomes in real-world patients with ATTR-CM
thumbnail
Congress Presentation
Improvements in cardiac functional status and health-related quality of life in patients receiving early access tafamidis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources